Northeast Pharmaceutical Co., Ltd (SHE: 000597), a Chinese pharmaceutical company, has announced plans to acquire a 70% stake in Beijing Dingcheng Taiyuan Biotechnology Co., Ltd, a biotech firm specializing in cell therapies for solid tumors. Financial details of the transaction have not been disclosed.
Established in 2014, Dingcheng Taiyuan has been at the forefront of developing and translating cell therapies for various cancers, including pancreatic, colorectal, gastric, liver, and glioma. The company’s portfolio encompasses over 10 cell therapy products, which include TCR-T, TCR, and innovative CAR-T therapies. These therapies target specific mutations such as KRAS, EGFRvIII, AFP, and Claudin18.2. Dingcheng Taiyuan also operates a translation platform that encompasses plasmid technology, virus technology, cell technology, and quality research.
Among its pipeline, DCTY1102, a TCR-T therapy aimed at KRAS G12D, is under review for clinical trials in China. Additionally, the CAR-T therapy DCTY0801, which is under Investigational New Drug (IND) review in both China and the U.S., has received orphan drug designation (ODD) in the U.S. for the treatment of glioblastoma, highlighting the potential impact of its therapies on rare and hard-to-treat cancers.- Flcube.com
